First Albany Keeps 'Buy' on Xoma

Analyst David Webber cites the drugmaker's positive FDA panel review for psoriasis treatment Raptiva

First Albany reiterates buy on Xoma (XOMA ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.